Literature DB >> 12829413

Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra.

J Andrés Abin-Carriquiry1, Ronald McGregor-Armas, Gustavo Costa, Jessika Urbanavicius, Federico Dajas.   

Abstract

While nicotine, through stimulation of a specific sub-population of nicotinic acetylcholine receptors (nAChR) appears to protect cells in culture against a variety of insults, studies in vivo show controversial results. In a previous paper we have shown that in the 6-hydroxydopamine (6-OHDA) model of experimental parkinsonism, an intermittent administration schedule of nicotine (4 h before and 20, 44 and 68 h after 6-OHDA) was able to prevent the decrease of dopamine (DA) concentration in the corpus striatum (CS) provoked by the partial lesion of the substantia nigra (50% neuronal death after 6 micro g of 6-OHDA). To further analyze the mechanisms of nicotine effects, we performed a microdialysis study of striatal extracellular DA concentrations utilizing the nicotine administration schedule that was able to prevent DA decrease. Basal extracellular DA concentrations in the CS were maintained after 6-OHDA and were not modified by nicotine. Basal DOPAC levels were decreased after the neurotoxic administration. The response of extracellular DA to potassium chloride (KCl) challenge was significantly lower after 6-OHDA than in control animals. Nicotine significantly reversed this decrease. As previous studies have shown, the striatal DA terminals surviving the 6-OHDA toxic effect are able to keep extracellular DA concentrations close to normal, likely increasing DA synthesis. Nevertheless, the application of a releasing factor such as KCl shows the fragility of this equilibrium, exposing a decrease in the terminal number. Nicotine, through a further activation of tyrosine hydroxylase and DA synthesis or by prolonging the life of DA terminals, could reverse the effect of 6-OHDA.

Entities:  

Year:  2002        PMID: 12829413     DOI: 10.1080/10298420290015863

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  40 in total

1.  Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.

Authors:  G Costa; J A Abin-Carriquiry; F Dajas
Journal:  Brain Res       Date:  2001-01-12       Impact factor: 3.252

2.  Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.

Authors:  C Rosenblad; D Kirik; A Björklund
Journal:  Exp Neurol       Date:  2000-02       Impact factor: 5.330

3.  In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.

Authors:  A F Hoffman; C G van Horne; S Eken; B J Hoffer; G A Gerhardt
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

4.  GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.

Authors:  J Opacka-Juffry; S Ashworth; S P Hume; D Martin; D J Brooks; S B Blunt
Journal:  Neuroreport       Date:  1995-12-29       Impact factor: 1.837

5.  The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism.

Authors:  F A Dajas-Bailador; P A Lima; S Wonnacott
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

6.  Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons.

Authors:  R Garrido; A Malecki; B Hennig; M Toborek
Journal:  Brain Res       Date:  2000-04-07       Impact factor: 3.252

7.  Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors.

Authors:  R Maggio; M Riva; F Vaglini; F Fornai; R Molteni; M Armogida; G Racagni; G U Corsini
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

8.  The in vivo microdialysis recovery of dopamine is altered independently of basal level by 6-hydroxydopamine lesions to the nucleus accumbens.

Authors:  L H Parsons; A D Smith; J B Justice
Journal:  J Neurosci Methods       Date:  1991-12       Impact factor: 2.390

9.  Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity.

Authors:  P Marin; M Maus; S Desagher; J Glowinski; J Prémont
Journal:  Neuroreport       Date:  1994-10-03       Impact factor: 1.837

10.  Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

Authors:  R A Behmand; S I Harik
Journal:  J Neurochem       Date:  1992-02       Impact factor: 5.372

View more
  7 in total

1.  Neurotoxicological and neuroprotective elements in Parkinson's disease.

Authors:  Richard M. Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

Review 2.  Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance.

Authors:  Merouane Bencherif
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

Review 3.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

Review 4.  Multiple roles for nicotine in Parkinson's disease.

Authors:  Maryka Quik; Luping Z Huang; Neeraja Parameswaran; Tanuja Bordia; Carla Campos; Xiomara A Perez
Journal:  Biochem Pharmacol       Date:  2009-05-09       Impact factor: 5.858

Review 5.  Nicotinic receptors as CNS targets for Parkinson's disease.

Authors:  Maryka Quik; Tanuja Bordia; Kathryn O'Leary
Journal:  Biochem Pharmacol       Date:  2007-06-17       Impact factor: 5.858

6.  Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.

Authors:  Luping Z Huang; Neeraja Parameswaran; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2009-02-24       Impact factor: 5.372

Review 7.  Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.

Authors:  Xiomara A Perez
Journal:  Neuropsychol Rev       Date:  2015-11-09       Impact factor: 7.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.